| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.85 [0.72, 1.01] | | < 1 | | 0% | 2 studies (2/-) | 96.4 % | low | not evaluable | high | crucial | - |
| PFS (extension) | 0.80 [0.69, 0.92] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.80 [0.69, 0.92] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
| DOR | 0.78 [0.63, 0.97] | | < 1 | | 0% | 1 study (1/-) | 98.6 % | NA | not evaluable | | non important | - |
| events or deaths (EFS) | 0.76 [0.40, 1.44] | | < 1 | | 0% | 1 study (1/-) | 79.9 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 1.52 [1.17, 1.98] | | > 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| pCR | 1.95 [1.26, 3.01] | | > 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.47 [0.72, 8.47] | | < 1 | | 0% | 2 studies (2/-) | 7.5 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 1.25 [1.00, 1.57] | | < 1 | | 0% | 2 studies (2/-) | 2.7 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 1.71 [0.49, 5.92] | | < 1 | | 0% | 2 studies (2/-) | 20.1 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.66 [0.89, 3.11] | | < 1 | | 71% | 2 studies (2/-) | 5.6 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 1.55 [1.05, 2.29] | | < 1 | | 43% | 2 studies (2/-) | 1.4 % | low | not evaluable | high | non important | - |
| STRAE (any grade) | 1.72 [1.21, 2.45] | | < 1 | | 0% | 2 studies (2/-) | 0.1 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 1.70 [0.93, 3.11] | | < 1 | | 0% | 2 studies (2/-) | 4.2 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 1.39 [1.08, 1.80] | | < 1 | | 13% | 2 studies (2/-) | 0.6 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 2.91 [0.30, 28.05] | | < 1 | | 0% | 1 study (1/-) | 18.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 0.51 [0.02, 15.24] | | < 1 | | 0% | 1 study (1/-) | 65.0 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.02 [0.06, 16.42] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 1.02 [0.32, 3.23] | | < 1 | | 0% | 1 study (1/-) | 48.7 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 0.96 [0.06, 15.47] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Abdominal pain AE (grade 3-4) | 1.24 [0.17, 8.82] | | < 1 | | 0% | 2 studies (2/-) | 41.6 % | low | not evaluable | high | non important | - |
| Acute kidney injury AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 1.62 [0.21, 12.61] | | < 1 | | 0% | 2 studies (2/-) | 32.3 % | low | not evaluable | high | non important | - |
| Anaemia AE (grade 3-4) | 1.12 [0.64, 1.94] | | < 1 | | 0% | 2 studies (2/-) | 34.9 % | low | not evaluable | high | non important | - |
| Arthralgia AE (grade 3-4) | 0.98 [0.10, 9.47] | | < 1 | | 0% | 2 studies (2/-) | 50.6 % | low | not evaluable | high | non important | - |
| Asthenia AE (grade 3-4) | 0.98 [0.31, 3.12] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Back pain AE (grade 3-4) | 2.51 [0.57, 11.10] | | < 1 | | 0% | 2 studies (2/-) | 11.3 % | low | not evaluable | high | non important | - |
| Cardiomyopathy AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Chills AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 0.96 [0.06, 15.47] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 1.70 [0.26, 11.21] | | < 1 | | 0% | 2 studies (2/-) | 29.2 % | low | not evaluable | high | non important | - |
| Cough AE (grade 3-4) | 0.99 [0.06, 15.89] | | < 1 | | 0% | 2 studies (2/-) | 50.2 % | low | not evaluable | high | non important | - |
| Decreased appetite AE (grade 3-4) | 0.97 [0.22, 4.30] | | < 1 | | 0% | 2 studies (2/-) | 51.5 % | low | not evaluable | high | non important | - |
| Diarrhoea AE (grade 3-4) | 1.36 [0.33, 5.60] | | < 1 | | 40% | 2 studies (2/-) | 33.4 % | low | not evaluable | high | non important | - |
| Dizziness AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Dry skin AE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Dysgeusia AE (grade 3-4) | 0.99 [0.06, 15.89] | | < 1 | | 0% | 2 studies (2/-) | 50.2 % | low | not evaluable | high | non important | - |
| Dyspepsia AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Dysphonia AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.99 [0.28, 3.42] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | low | not evaluable | high | non important | - |
| Epistaxis AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.13 [0.61, 2.08] | | < 1 | | 0% | 2 studies (2/-) | 34.8 % | low | not evaluable | high | non important | - |
| Febrile neutropenia AE (grade 3-4) | 1.25 [0.61, 2.57] | | < 1 | | 0% | 1 study (1/-) | 27.3 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.49 [0.11, 2.23] | | < 1 | | 0% | 2 studies (2/-) | 82.3 % | low | not evaluable | high | non important | - |
| Hypertension AE (grade 3-4) | 0.59 [0.25, 1.38] | | < 1 | | 31% | 2 studies (2/-) | 89.0 % | low | not evaluable | high | non important | - |
| Hyperthyroidism AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 1.33 [0.56, 3.16] | | < 1 | | 17% | 2 studies (2/-) | 25.9 % | low | not evaluable | high | non important | - |
| Increased ALT AE (grade 3-4) | 1.13 [0.55, 2.31] | | < 1 | | 0% | 2 studies (2/-) | 36.8 % | low | not evaluable | high | non important | - |
| Infusion-related reaction AE (grade 3-4) | 1.02 [0.06, 16.42] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
| Lacrimation increased AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 1.73 [0.86, 3.49] | | < 1 | | 0% | 2 studies (2/-) | 6.3 % | low | not evaluable | high | non important | - |
| Mucosal inflammation AE (grade 3-4) | 1.96 [0.43, 8.98] | | < 1 | | 0% | 2 studies (2/-) | 19.4 % | low | not evaluable | high | non important | - |
| Myalgia AE (grade 3-4) | 0.83 [0.17, 4.04] | | < 1 | | 0% | 2 studies (2/-) | 59.3 % | low | not evaluable | high | non important | - |
| Myopathy AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.47 [0.19, 1.17] | | < 1 | | 0% | 2 studies (2/-) | 94.9 % | low | not evaluable | high | non important | - |
| Neutropenia AE (grade 3-4) | 1.05 [0.74, 1.50] | | < 1 | | 0% | 2 studies (2/-) | 38.3 % | low | not evaluable | high | non important | - |
| Oropharyngeal pain AE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Paraesthesia AE (grade 3-4) | 1.62 [0.21, 12.61] | | < 1 | | 0% | 2 studies (2/-) | 32.3 % | low | not evaluable | high | non important | - |
| Pericarditis AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 1.09 [0.23, 5.23] | | < 1 | | 69% | 2 studies (2/-) | 45.9 % | low | not evaluable | high | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.22 [0.04, 1.33] | | < 1 | | 0% | 2 studies (2/-) | 95.0 % | low | not evaluable | high | non important | - |
| Peripheral sensory neuropathy AE (grade 3-4) | 1.28 [0.34, 4.86] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 3.27 [0.89, 11.95] | | < 1 | | 0% | 1 study (1/-) | 3.7 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 3.87 [0.17, 86.09] | | < 1 | | 0% | 1 study (1/-) | 19.9 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.35 [0.05, 2.36] | | < 1 | | 0% | 2 studies (2/-) | 86.0 % | low | not evaluable | high | non important | - |
| Pyrexia AE (grade 3-4) | 4.92 [0.57, 42.55] | | < 1 | | 0% | 2 studies (2/-) | 7.5 % | low | not evaluable | high | non important | - |
| Rash AE (grade 3-4) | 1.84 [0.43, 7.98] | | < 1 | | 0% | 2 studies (2/-) | 20.8 % | low | not evaluable | high | non important | - |
| Sepsis AE (grade 3-4) | 0.16 [0.01, 3.20] | | < 1 | | 0% | 1 study (1/-) | 88.2 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 2.27 [0.30, 17.45] | | < 1 | | 0% | 2 studies (2/-) | 21.6 % | low | not evaluable | high | non important | - |
| Thrombocytopenia AE (grade 3-4) | 1.93 [0.17, 21.40] | | < 1 | | 0% | 1 study (1/-) | 29.7 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.97 [0.30, 3.07] | | < 1 | | 0% | 2 studies (2/-) | 52.4 % | low | not evaluable | high | non important | - |
| Weight decreased AE (grade 3-4) | 5.82 [0.29, 116.53] | | < 1 | | 0% | 1 study (1/-) | 12.7 % | NA | not evaluable | | non important | - |
